348 related articles for article (PubMed ID: 15888422)
1. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Buchanan RW; Davis M; Goff D; Green MF; Keefe RS; Leon AC; Nuechterlein KH; Laughren T; Levin R; Stover E; Fenton W; Marder SR
Schizophr Bull; 2005 Jan; 31(1):5-19. PubMed ID: 15888422
[TBL] [Abstract][Full Text] [Related]
2. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Buchanan RW; Keefe RS; Umbricht D; Green MF; Laughren T; Marder SR
Schizophr Bull; 2011 Nov; 37(6):1209-17. PubMed ID: 20410237
[TBL] [Abstract][Full Text] [Related]
3. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
4. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
[TBL] [Abstract][Full Text] [Related]
5. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.
Marder SR; Fenton W
Schizophr Res; 2004 Dec; 72(1):5-9. PubMed ID: 15531402
[TBL] [Abstract][Full Text] [Related]
6. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
Marder SR
Dialogues Clin Neurosci; 2006; 8(1):109-13. PubMed ID: 16640121
[TBL] [Abstract][Full Text] [Related]
7. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
Bromley E
Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
[TBL] [Abstract][Full Text] [Related]
8. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design.
Burdick KE; Ketter TA; Goldberg JF; Calabrese JR
J Clin Psychiatry; 2015 Mar; 76(3):e342-50. PubMed ID: 25830456
[TBL] [Abstract][Full Text] [Related]
9. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
10. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
11. [Consensus-based guidelines on prostate biopsy].
Italian Panel on Prostate Biopsy
Arch Ital Urol Androl; 2005 Sep; 77(3 Suppl 1):1-2, preceding 1. PubMed ID: 16402723
[TBL] [Abstract][Full Text] [Related]
12. An industry perspective on the NIMH consensus statement on negative symptoms.
Alphs L
Schizophr Bull; 2006 Apr; 32(2):225-30. PubMed ID: 16469940
[TBL] [Abstract][Full Text] [Related]
13. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.
Kern RS; Green MF; Nuechterlein KH; Deng BH
Schizophr Res; 2004 Dec; 72(1):11-9. PubMed ID: 15531403
[TBL] [Abstract][Full Text] [Related]
14. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004.
Montgomery SA; van Zwieten-Boot B
Eur Neuropsychopharmacol; 2007 Jan; 17(1):70-7. PubMed ID: 16842980
[No Abstract] [Full Text] [Related]
15. The NIMH-MATRICS consensus statement on negative symptoms.
Kirkpatrick B; Fenton WS; Carpenter WT; Marder SR
Schizophr Bull; 2006 Apr; 32(2):214-9. PubMed ID: 16481659
[No Abstract] [Full Text] [Related]
16. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
[TBL] [Abstract][Full Text] [Related]
17. Methodological issues in negative symptom trials.
Marder SR; Daniel DG; Alphs L; Awad AG; Keefe RS
Schizophr Bull; 2011 Mar; 37(2):250-4. PubMed ID: 21270473
[TBL] [Abstract][Full Text] [Related]
18. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.
Cho RY; Ford JM; Krystal JH; Laruelle M; Cuthbert B; Carter CS
Schizophr Bull; 2005 Oct; 31(4):865-9. PubMed ID: 16166611
[TBL] [Abstract][Full Text] [Related]
19. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness.
Marder SR
J Clin Psychiatry; 2006 Jul; 67(7):e03. PubMed ID: 17107228
[TBL] [Abstract][Full Text] [Related]
20. New paradigms for treatment development.
Stover EL; Brady L; Marder SR
Schizophr Bull; 2007 Sep; 33(5):1093-9. PubMed ID: 17673495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
